Last reviewed · How we verify
Pemetrexed 500 mg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pemetrexed 500 mg (Pemetrexed 500 mg) — Latin American Cooperative Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pemetrexed 500 mg TARGET | Pemetrexed 500 mg | Latin American Cooperative Oncology Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pemetrexed 500 mg CI watch — RSS
- Pemetrexed 500 mg CI watch — Atom
- Pemetrexed 500 mg CI watch — JSON
- Pemetrexed 500 mg alone — RSS
Cite this brief
Drug Landscape (2026). Pemetrexed 500 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-500-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing